EGFR and lung adenocarcinoma: The EGFR gene mutation rates are 40% to 50% in Asian and Chinese patients with lung adenocarcinoma.11, 12 Multiple randomized stage III clinical studies13, 14, 15, 16, 17, 18, 19, 20 have revealed that treatment with EGFR‐TKIs (gefitinib, erlotinib, ectinib, afatinib, etc) improves progression‐free survival.